News
NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.
The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).
EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II and is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: NeuroScientific soars 10pc on COVID-19 drug, Telix advances prostate cancer studies
Stockhead TV
90 Seconds With… Paul Rennie from Neuroscientific biopharmaceuticals (ASX:NSB)
Health & Biotech
Neuroscientific Biopharmaceuticals’ lead drug candidate passes safety and tolerance study with flying colours
Health & Biotech
ScoPo’s Powerplays: Buying opportunities in a volatile week
Health & Biotech
Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
Health & Biotech
NeuroScientific Biopharmaceuticals now has a research partner for its Phase I EmtinB trial
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
NeuroScientific Biopharmaceuticals recruits Paradigm’s Paul Rennie as non-executive chairman
News
Market highlights and 5 ASX small caps to watch on Wednesday
News
Market Highlights and 4 ASX Small Caps to watch on Wednesday
Health & Biotech
Neuroscientific has ‘great confidence’ in possible glaucoma treatment
Health & Biotech
HealthKick Podcast: NSB brings new solutions to medicine’s most stubborn eye problems
Health & Biotech
Neuroscientific is researching a potential cure for post-COVID lung damage
News
Tech space has its day in Perth sun
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
News